CLVT vs. MEDP, WPP, HQY, BILI, QXO, ETSY, GLOB, LYFT, AMTM, and MARA
Should you be buying Clarivate stock or one of its competitors? The main competitors of Clarivate include Medpace (MEDP), WPP (WPP), HealthEquity (HQY), Bilibili (BILI), QXO (QXO), Etsy (ETSY), Globant (GLOB), Lyft (LYFT), Amentum (AMTM), and MARA (MARA). These companies are all part of the "business services" industry.
Clarivate vs.
Clarivate (NYSE:CLVT) and Medpace (NASDAQ:MEDP) are both mid-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.
Medpace has a net margin of 19.17% compared to Clarivate's net margin of -24.90%. Medpace's return on equity of 51.48% beat Clarivate's return on equity.
Clarivate currently has a consensus target price of $5.83, suggesting a potential upside of 34.41%. Medpace has a consensus target price of $349.30, suggesting a potential upside of 14.36%. Given Clarivate's higher probable upside, analysts clearly believe Clarivate is more favorable than Medpace.
Medpace has lower revenue, but higher earnings than Clarivate. Clarivate is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace received 305 more outperform votes than Clarivate when rated by MarketBeat users. Likewise, 62.81% of users gave Medpace an outperform vote while only 53.33% of users gave Clarivate an outperform vote.
85.7% of Clarivate shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 23.2% of Clarivate shares are held by company insiders. Comparatively, 20.3% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Clarivate has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
In the previous week, Medpace had 27 more articles in the media than Clarivate. MarketBeat recorded 42 mentions for Medpace and 15 mentions for Clarivate. Clarivate's average media sentiment score of 0.57 beat Medpace's score of 0.50 indicating that Clarivate is being referred to more favorably in the media.
Summary
Medpace beats Clarivate on 12 of the 18 factors compared between the two stocks.
Get Clarivate News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clarivate Competitors List
Related Companies and Tools
This page (NYSE:CLVT) was last updated on 4/30/2025 by MarketBeat.com Staff
Buy CLVT Stock Free CLVT Stock Alerts